Researchers at Johns Hopkins Medicine have uncovered a potential way to make mRNA therapies more potent, a discovery that could reshape the next generation of vaccines and treatments for cancer, infectious diseases, and autoimmune conditions. The study, published in Nature, focuses on a naturally occurring RNA modification known as N4-acetylcytidine, or ac4C, which appears to boost protein production inside cells.
Current mRNA platforms, including the ones used in COVID-19 vaccines, rely on a different modification called N1-methylpseudouridine, or m1Ψ. This chemical tweak helps the synthetic mRNA evade the immune system and improves stability, but the Johns Hopkins team found that ac4C may be even more effective at getting cells to churn out therapeutic proteins.
In experiments with cultured human dendritic cells and mouse liver cells, the researchers compared the two modifications. They observed that ribosomes—the cellular machines that read mRNA and assemble proteins—travel nearly twice as fast along ac4C-modified mRNA as they do along m1Ψ-modified mRNA. This speed, they suggest, prevents the ribosomal "traffic jams" that can occur with the standard platform.
"Our imaging revealed that ribosomes travel nearly twice as fast on the ac4C-modified mRNA, preventing the ribosomal traffic jam we may encounter with the industry standard mRNA platform," said Bin Wu, associate professor of biophysics and biophysical chemistry at the Johns Hopkins University School of Medicine.
The implications for the pharmaceutical industry are significant. mRNA technology works by instructing cells to temporarily produce a specific protein—such as a viral antigen or a tumor marker—to trigger an immune response. The amount of protein produced is often critical to whether a therapy works effectively. If ac4C can increase that output, future treatments might achieve the desired effect with smaller doses, reducing costs and side effects.
This could matter across a growing pipeline of mRNA medicines, from vaccines against infectious diseases to experimental therapies designed to stimulate the immune system against cancer or to modulate immune responses in autoimmune conditions. The European Union has been a major hub for mRNA research and manufacturing, with companies like BioNTech in Mainz and CureVac in Tübingen leading the way. A breakthrough like this could influence how these firms design their next-generation products.
However, ac4C remains experimental. The researchers caution that much more work is needed to determine whether the modification is safe and effective in living organisms, not just in cultured cells. "There are more than 170 known RNA modifications, but only a small subset have been studied for mRNA therapeutic purposes," Wu noted. "ac4C may enhance mRNA translation, thereby having the potential to speed up and build proteins."
The study's findings also raise broader questions about the limits of current mRNA platforms. If the "traffic jam" identified by the team proves to be a real bottleneck in m1Ψ-based therapies, then ac4C could offer a simple fix—a swap of one chemical group for another. That would be a surprisingly small change with potentially large consequences.
For now, the race to build the next generation of mRNA medicines continues. European regulators and companies are watching closely, as the continent has invested heavily in mRNA technology since the pandemic. The possibility of more efficient drugs could also have implications for global vaccine equity, as smaller doses would stretch supply further.
While the research is still in its early stages, the potential is clear. As Wu put it, "This may eventually lead to more efficient drugs that require smaller doses." If further studies confirm the promise of ac4C, it could become a cornerstone of future mRNA therapeutics, benefiting patients across Europe and beyond.
